Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKinsey
Mallinckrodt
Baxter
AstraZeneca

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR PIROXICAM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Piroxicam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00222183 ↗ Cutaneous Lupus Erythematosus and Elidel Withdrawn Novartis N/A 2003-06-01 This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
NCT00222183 ↗ Cutaneous Lupus Erythematosus and Elidel Withdrawn University of Leipzig N/A 2003-06-01 This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
NCT00530387 ↗ Multi-Centre European Photopatch Test Study Completed NHS Tayside N/A 2008-07-01 It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis. Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing. The study will run for one year, during which time it is planned to recruit 1,000 patients.
NCT00631514 ↗ Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed Dr Ivancica Pavlicevic Family Practice Office Phase 4 2005-01-01 NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
NCT00631514 ↗ Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed University Hospital of Split Phase 4 2005-01-01 NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
NCT00631514 ↗ Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed University of Split Phase 4 2005-01-01 NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
NCT00649415 ↗ A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Completed Pfizer Phase 4 2003-01-01 To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Piroxicam

Condition Name

Condition Name for Piroxicam
Intervention Trials
Postoperative Pain 3
Pain 2
Post-operative Endodontic Pain 1
Cesarean Section; Complications, Wound, Infection (Following Delivery) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Piroxicam
Intervention Trials
Pulpitis 3
Pain, Postoperative 3
Neoplasm Metastasis 2
Emergencies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Piroxicam

Trials by Country

Trials by Country for Piroxicam
Location Trials
Brazil 10
Tunisia 3
Germany 2
Egypt 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Piroxicam

Clinical Trial Phase

Clinical Trial Phase for Piroxicam
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2/Phase 3 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Piroxicam
Clinical Trial Phase Trials
Completed 18
Unknown status 5
Recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Piroxicam

Sponsor Name

Sponsor Name for Piroxicam
Sponsor Trials
Fundação de Amparo à Pesquisa do Estado de São Paulo 3
Cairo University 3
University of Monastir 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Piroxicam
Sponsor Trials
Other 32
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Baxter
Mallinckrodt
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.